Amryt, Aegerion sign expanded deal for Lojuxta capsules

This article was originally published here

Amryt has signed an agreement with Aegerion Pharmaceuticals to expand its exclusive licence agreement for Lojuxta (lomitapide) into Russia and the Commonwealth of Independent States (CIS), as well as the non-EU Balkan states.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply